Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC — Stella

Home/Head and Neck Squamous Cell Carcinoma (HNSCC)/Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

View on ClinicalTrials.gov

Recruiting

Back to Head and Neck Squamous Cell Carcinoma (HNSCC) trials

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Brigham and Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Safety & dosing

Sponsor

Dana-Farber Cancer Institute

Collaborators

Bicara Therapeutics

Enrollment target

~32 participants

Started

March 2026

Primary completion

April 2028

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.